Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.41 |
| ▸ | CBFB | Q13951 | 2/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916036 | 0.85 | MEN1 (0.47) | METALDH1A1F2GLAHPGD | |
| SCHEMBL10283506 | 0.84 | ALDH1A1 (0.52) | METALDH1A1F2GLAHPGD | |
| SCHEMBL13619433 | 0.80 | MET (0.45) | METCYP3A4ALDH1A1F2GLA | |
| SCHEMBL187290 | 0.78 | CBFB (0.57) | METCYP3A4ALDH1A1F2GLA | |
| SCHEMBL358693 | 0.77 | CNR1 (0.47) | METCYP3A4ALDH1A1F2GLA | |
| SCHEMBL187431 | 0.77 | FBP1 (0.44) | METCYP3A4ALDH1A1F2GLA | |
| SCHEMBL358992 | 0.77 | EGFR (0.42) | METALDH1A1F2GLAHPGD | |
| SCHEMBL186985 | 0.77 | PDGFRB (0.43) | METCYP3A4ALDH1A1F2GLA | |
| SCHEMBL359221 | 0.76 | ALDH1A1 (0.50) | METCYP3A4ALDH1A1F2GLA | |
| SCHEMBL370132 | 0.76 | CBFB (0.46) | METCYP3A4ALDH1A1F2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-2310389-B1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2310389-B1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2310389-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009143477-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143477-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | HGF, HGFAC, MET | MET 3/4885CYP3A4 1277/4885ALDH1A1 1377/4885 |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | MET 3/4885CYP3A4 4244/4885ALDH1A1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.